Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 37 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dexcom's reported carbon emissions
In 2023, Dexcom reported total carbon emissions of approximately 6,652,000,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions accounted for about 6,652,000,000 kg CO2e, while Scope 2 emissions were approximately 25,291,000 kg CO2e (market-based). Scope 3 emissions were notably high at around 479,576,000,000 kg CO2e, primarily driven by waste generated in operations. Comparatively, in 2022, Dexcom's total emissions were about 4,768,000,000 kg CO2e for Scope 1, approximately 13,610,000 kg CO2e for Scope 2, and around 1,749,000,000 kg CO2e for Scope 3. This indicates a substantial increase in emissions across all scopes, particularly in Scope 3. Dexcom has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company is actively engaged in sustainability initiatives within the healthcare equipment and supplies sector, reflecting its commitment to addressing climate change. However, it has not yet committed to a net-zero target. Overall, Dexcom's emissions data highlights the challenges faced in reducing carbon footprints, particularly in Scope 3 emissions, which often represent the largest share of a company's total emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 2,044,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
